Neo-Synalar

Otitis Externa, Uveitis, Perianal erythema + 30 more

Treatment

3 FDA approvals

20 Active Studies for Neo-Synalar

What is Neo-Synalar

Fluocinolone acetonide

The Generic name of this drug

Treatment Summary

Fluocinolone acetonide is a steroid used in some skin treatments and implantable devices. This drug was developed by Taro Pharmaceuticals, and it was approved by the FDA in 2016. It is known for its high lipophilicity, which means it is very soluble in fat.

Neo-Synalar

is the brand name

image of different drug pills on a surface

Neo-Synalar Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Neo-Synalar

Fluocinolone acetonide

1963

93

Approved as Treatment by the FDA

Fluocinolone acetonide, otherwise called Neo-Synalar, is approved by the FDA for 3 uses like Chronic Uveitis and Uveitis .

Chronic Uveitis

Uveitis

Uveitis

Effectiveness

How Neo-Synalar Affects Patients

Fluocinolone acetonide is a type of steroid medicine that helps reduce inflammation. It is usually given as an intravitreal micro-insert for ophthalmic purposes. Studies have shown that this medicine reduces the number of uveitis flares by twofold in comparison to those that don't receive the treatment, and can be effective for up to six months. It is possible for the intraocular pressure to increase slightly when taking this medicine, so it is important to monitor it closely.

How Neo-Synalar works in the body

Fluocinolone acetonide is a corticosteroid, meaning it lowers inflammation. It works by binding to the glucocorticoid receptor in the cell nucleus, which activates certain proteins called lipocortins. These proteins stop the release of arachidonic acid, which is the first step in creating inflammatory molecules like prostaglandins and leukotrienes.

When to interrupt dosage

The advised dose of Neo-Synalar is contingent upon the diagnosed disorder, such as Hemorrhoids, Perianal erythema and Itch. The amount of dosage is dictated by the technique of delivery (e.g. Kit or Emulsion - Topical) provided in the table underneath.

Condition

Dosage

Administration

Pressure Ulcer

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Conjunctivitis, Bacterial

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Skin

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Skin Inflammation caused by Bacterial Infections

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Uveitis

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Diabetic Macular Edema

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Postoperative Care

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Eczema

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Dermatitis, Seborrheic

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Otitis Externa

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Uveitis

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Otitis Media

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Chronic disease

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Surgery; Ear

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

postoperative treatment

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Ear structure

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Wound Infection

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Perianal erythema

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Scab

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Itching

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit - Topical, Kit, Shampoo, Shampoo - Topical, Solution - Auricular (otic), Auricular (otic), Oil, Oil - Topical, Implant - Intravitreal, Intravitreal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Oil - Auricular (otic), Implant, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Warnings

Neo-Synalar Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Fluocinolone Acetonide may interact with conjunctiva

Mycoses

Do Not Combine

External auditory canal structure

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Fluocinolone Acetonide may interact with conjunctiva

There are 20 known major drug interactions with Neo-Synalar.

Common Neo-Synalar Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Fluocinolone acetonide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Abetimus.

Neo-Synalar Toxicity & Overdose Risk

No studies have been conducted to determine the effect of fluocinolone acetonide on fertility or its potential to cause cancer. However, some corticosteroids have been found to be genotoxic, while fluocinolone acetonide was not shown to be genotoxic in tests using bacteria and mice.

image of a doctor in a lab doing drug, clinical research

Neo-Synalar Novel Uses: Which Conditions Have a Clinical Trial Featuring Neo-Synalar?

There are 97 active clinical trials investigating the potential of Neo-Synalar to ameliorate Atopic Dermatitis, Otitis Media and Otitis Externa.

Condition

Clinical Trials

Trial Phases

Hemorrhoids

1 Actively Recruiting

Not Applicable

Perianal erythema

0 Actively Recruiting

Eczema

0 Actively Recruiting

Blister

0 Actively Recruiting

Otitis Externa

0 Actively Recruiting

Psoriasis of the scalp

1 Actively Recruiting

Phase 4

Otitis

3 Actively Recruiting

Not Applicable

Hemorrhoids

0 Actively Recruiting

Scab

0 Actively Recruiting

Ear structure

0 Actively Recruiting

Skin

0 Actively Recruiting

Skin Diseases

0 Actively Recruiting

Fissure in Ano

0 Actively Recruiting

Postoperative Care

4 Actively Recruiting

Early Phase 1, Phase 4, Not Applicable

Wound Infection

0 Actively Recruiting

Skin Inflammation caused by Bacterial Infections

0 Actively Recruiting

Uveitis

3 Actively Recruiting

Not Applicable, Phase 3

Conjunctivitis, Bacterial

0 Actively Recruiting

Coinfection

0 Actively Recruiting

Chronic disease

0 Actively Recruiting

Neo-Synalar Reviews: What are patients saying about Neo-Synalar?

5

Patient Review

7/11/2016

Neo-Synalar for Minor Skin Infection caused by Bacteria

While this treatment is easy to use, it's slow in clearing up blemishes. That said, it does reduce redness significantly. The price tag is absolutely insane though; I could never justify spending that much on a skincare product.

5

Patient Review

2/17/2019

Neo-Synalar for Minor Skin Infection caused by Bacteria

I had some really weird gray, very itchy bumps that developed in my armpits. A sample of this cleared it up in no time. Insurance would not pay (Why???) why is a topical cream so crazy expensive?

3.7

Patient Review

1/19/2015

Neo-Synalar for Minor Skin Infection caused by Bacteria

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about neo-synalar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can Neo-Synalar be used on the face?

"Do not use Neo-Synalar to treat any skin condition on your face, underarms, or groin area without checking with your doctor first."

Answered by AI

Is Neo-Synalar a steroid?

"Neo-Synalar is a prescription cream made of two medications, a steroid and an antibiotic. It's used to treat certain skin conditions that become infected."

Answered by AI

What is Neo-Synalar used for?

"This medication is used to treat certain skin infections by containing neomycin, an antibiotic that works to stop the growth of bacteria. It also contains a medium-strength corticosteroid, fluocinolone, that helps reduce the swelling, itching, and redness of the skin."

Answered by AI

Clinical Trials for Neo-Synalar

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Image of University of California, Los Angeles in Los Angeles, United States.

Hemorrhoidal Artery Embolization for Hemorrhoids

18 - 90
All Sexes
Los Angeles, CA

Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.

Recruiting
Has No Placebo

University of California, Los Angeles

Lucas Cusumano, MD

Have you considered Neo-Synalar clinical trials?

We made a collection of clinical trials featuring Neo-Synalar, we think they might fit your search criteria.
Go to Trials
Image of The University of Alabama at Birmingham in Birmingham, United States.

Octreotide for Diabetic Macular Edema

18 - 90
All Sexes
Birmingham, AL

Treatment of diabetic retinopathy (DR) and diabetic macula edema has included panretinal photocoagulation and intra ocular injections of anti-vascular endothelial growth factors (anti-VEGF) agents and steroids. Anti-VEGF therapy is currently the first-line treatment for proliferative diabetic retinopathies; however, this approach is ineffective in more than 30% of patients with diabetic retinal complications. Available evidence shows that subcutaneous (under the skin) injection of octreotide, a somatostatin analog, has potential therapeutic benefits in proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME). This study thus seeks to determine the efficacy and safety of intranasal DDM-octreotide in the treatment of diabetic macula edema in individuals that are considered to be refractory to the current therapeutic options.

Phase 1
Waitlist Available

The University of Alabama at Birmingham

Maria Grant, MD, FARVO

Image of Associated Retinal Consultants PC in Phoenix, United States.

RO7446603 + Aflibercept/Faricimab for Diabetic Macular Edema

18+
All Sexes
Phoenix, AZ

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.

Phase 1 & 2
Recruiting

Associated Retinal Consultants PC (+70 Sites)

Clinical Trials

Genentech, Inc.

Image of Retinal Consultants of AZ, Ltd in Peoria, United States.

RO7497372 for Diabetic Macular Edema

18+
All Sexes
Peoria, AZ

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.

Phase 1
Waitlist Available

Retinal Consultants of AZ, Ltd (+36 Sites)

Clinical Trials

Genentech, Inc.

Have you considered Neo-Synalar clinical trials?

We made a collection of clinical trials featuring Neo-Synalar, we think they might fit your search criteria.
Go to Trials
Image of University of Virginia in Charlottesville, United States.

Methadone vs Remifentanil for Pain in Craniotomy Surgery

18 - 65
All Sexes
Charlottesville, VA

Postoperative pain is prevalent after intracranial surgery. Patients undergoing craniotomy are typically managed with short acting opioids to enable early and reliable post-operative neurological exam as well as avoid the risk of respiratory depression. However, a plethora of studies have shown that a majority of these patients experience moderate to severe pain in first 48 hours after surgery. Suboptimal pain control can lead to complications such as arterial hypertension and post-operative intracranial hemorrhage, and hence, increased morbidity and mortality. Intravenous (IV) methadone has a long analgesic half-life and has N-methyl-D-aspartate (NMDA) receptor antagonist and serotonin and norepinephrine reuptake inhibitor (SNRI) properties. It has previously been shown to reduce postoperative opioid requirements, postoperative nausea and vomiting (PONV), and postoperative pain scores in patients that underwent orthopedic, abdominal, complex spine, and cardiac surgery. Similar findings have been shown in obstetric patients that underwent caesarean delivery under general anesthesia as well as patients that underwent gynecologic surgery and received IV methadone intraoperatively. In a recently published retrospective study, a single intraoperative dose of IV methadone was well tolerated with lower pain scores as well as MME (oral morphine milligram equivalents) requirements for up to 72 hours after elective intracranial surgery. IV methadone has, however, never been compared with conventional management via IV remifentanil for functional recovery in patients undergoing elective intercranial surgery. The investigator's hypothesis is that intravenous (IV) methadone is non-inferior to IV remifentanil in patients who undergo elective intracranial surgery. It offers the advantage of being a single dose noninvasive analgesic modality that may contribute to decreasing MME consumption during the first 72 hours postoperatively, controlling postoperative pain, and improving quality of recovery after surgery.

Phase < 1
Waitlist Available

University of Virginia

Image of Scottsdale, Arizona in Scottsdale, United States.

EYE201 for Eye Conditions

18+
All Sexes
Scottsdale, AZ

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part, 2 doses of EYE201 will be selected and their effectiveness will be compared. This portion of the study assesses the safety and preliminary efficacy of EYE201 in patients with diabetic macular edema (DME) or neovascular macular degeneration (NVAMD). Approximately 80 participants will be entered in this part of the study.

Phase 1 & 2
Recruiting

Scottsdale, Arizona (+25 Sites)

EyeBiotech Ltd.

Have you considered Neo-Synalar clinical trials?

We made a collection of clinical trials featuring Neo-Synalar, we think they might fit your search criteria.
Go to Trials